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AbsTrACT
Objective Tanezumab, a nerve growth factor inhibitor, 
was investigated for osteoarthritis (Oa) of the hip or 
knee in a study with 24- week treatment and 24- week 
safety follow- up.
Methods This double- blind, randomised, phase 
iii study enrolled adults in europe and Japan with 
moderate- to- severe Oa who had not responded to or 
could not tolerate standard- of- care analgesics. Patients 
were randomised to tanezumab 2.5 mg or 5 mg 
subcutaneously or matching placebo every 8 weeks 
(three doses). Co- primary end points were change from 
baseline to week 24 in Western Ontario and McMaster 
Universities Osteoarthritis index (WOMaC) Pain and 
Physical Function, and Patient’s Global assessment 
of Oa (PGa- Oa). Joint safety and neurological 
assessments continued throughout the 48- week study.
results From March 2016 to December 2017, 849 
patients were randomised and evaluated (placebo n=282, 
tanezumab 2.5 mg n=283, tanezumab 5 mg n=284). at 
week 24, there was a statistically significant improvement 
from baseline for tanezumab 5 mg compared with placebo 
for WOMaC Pain (least squares mean difference±se 
–0.62±0.18, p=0.0006), WOMaC Physical Function 
(–0.71±0.17, p<0.0001) and PGa- Oa (–0.19±0.07, 
p=0.0051). For tanezumab 2.5 mg, there was a 
statistically significant improvement in WOMaC Pain and 
Physical Function, but not PGa- Oa. Rapidly progressive 
osteoarthritis (RPOa) was observed in 1.4% (4/283) and 
2.8% (8/284) of patients in the tanezumab 2.5 mg and 
tanezumab 5 mg groups, respectively and none receiving 
placebo. Total joint replacements (TJRs) were similarly 
distributed across all three treatment groups (6.7%–7.8%). 
Tanezumab- treated patients experienced more paraesthesia 
(5 mg) and hypoaesthesia (both doses) than placebo.
Conclusion Tanezumab 5 mg statistically significantly 
improved pain, physical function and PGa- Oa, but 
tanezumab 2.5 mg only achieved two co- primary 
end points. RPOa occurred more frequently with 
tanezumab 5 mg than tanezumab 2.5 mg. TJRs were 
similarly distributed across all three groups.
Trial registration number nCT02709486.
InTrOduCTIOn
Globally, osteoarthritis (OA) is a leading cause of 
disability1 with joint pain that often makes common 
Key messages
What is already known about this subject?
 ► A systematic review and meta- analysis of 
the efficacy and safety of tanezumab for 
osteoarthritis (OA), published in 2015, was 
based on a search of PubMed and Embase 
using relevant keywords (tanezumab, 
fulranumab, fasinumab, anti- nerve growth 
factor (NGF), NGF, osteoarthritis or OA) and lists 
of studies obtained from the developers.
 ► The authors imposed no eligibility restrictions 
on the age of participants, the duration of 
disease or concomitant medication use (non- 
steroidal anti- inflammatory drug or opioids), nor 
language or publication date/status restrictions.
 ► This systematic review showed that the 
early tanezumab studies investigated mostly 
intravenous administration with primary end 
points evaluated at 16 weeks.
 ► Doses were body weight- adjusted or 
administered as fixed doses (up to  
tanezumab 10 mg).
 ► The few studies performed using subcutaneous 
injection were impacted by temporary partial 
clinical holds placed on non- cancer pain studies 
of all NGF monoclonal antibodies following 
joint safety findings in clinical trials, which were 
adjudicated as rapidly progressive osteoarthritis, 
and concerns regarding histomorphological 
changes in the sympathetic nervous system 
reported in preclinical studies.
 ► After a comprehensive assessment of the 
clinical data related to joint safety and 
neurological safety as well as additional 
preclinical studies of sympathetic nervous 
system morphology and function, a risk 
minimisation plan including comprehensive 
surveillance for joint safety and sympathetic 
neurological safety was implemented.
 ► The phase III OA programme conducted post-
2015 used only lower doses of tanezumab 
administered subcutaneously in difficult- to- 
treat patients, and incorporated extensive risk 
management procedures to maintain patient 
safety.
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Figure 1 Study design. Scheduled in- clinic visits occurred at screening, baseline and weeks 2, 4, 8, 12, 16, 24, 32 and 48, with telephone contact 
scheduled for weeks 20, 28, 36, 40 and 44. Patients who did not complete the double- blind treatment period were still followed through the 24- week 
safety follow- up period.
Key messages
What does this study add?
 ► Of the phase III OA programme, this is the first study to 
assess the efficacy of tanezumab 2.5 mg and 5 mg every 8 
weeks for 24 weeks with additional 24- week safety follow- 
up in patients with moderate- to- severe OA and inadequate 
response to standard- of- care analgesics.
How might this impact on clinical practice or future 
developments?
 ► This study demonstrates the efficacy of subcutaneous 
tanezumab in difficult- to- treat patients with OA.
 ► Adjudicated joint safety end points occurred only in 
tanezumab- treated patients.
 ► Total joint replacements were similarly distributed across all 
three treatment groups.
 ► A longer- term active- controlled study (ClinicalTrials.gov, 
NCT02528188) will provide data to further characterise the 
risk- benefit of tanezumab in patients with OA. 
daily activities difficult. Patients with knee or hip OA also have 
a higher risk of mortality than the general population due to 
increased cardiovascular events.2
To manage the pain associated with OA, guidelines recommend 
a combination of non- pharmacological approaches and analge-
sics3 4 including acetaminophen (paracetamol), non- steroidal 
anti- inflammatory drugs (NSAIDs) and opioids. Limited efficacy 
in some patients and concerns about adverse effects5 6 mean that 
an alternative to current pharmacological treatment options is 
needed.
Nerve growth factor (NGF) is involved in pain signalling7 and 
has been implicated in OA pain.8 Early clinical trials of the NGF 
monoclonal antibody tanezumab investigated mostly intrave-
nous administration of doses that were body weight- adjusted or 
administered as a fixed dose (up to 10 mg), and used primary 
efficacy end points measured at 16 weeks or earlier.9 Cases of 
rapidly progressive osteoarthritis (RPOA) were observed in 
some of these studies.10 Due to these joint safety concerns and 
histomorphological changes in the sympathetic nervous system 
observed in preclinical animal studies,11 the US Food and Drug 
Administration placed partial clinical holds on studies of NGF 
antibodies in 2010 and 2012, respectively. Investigation of these 
events provided evidence that led to the subsequent lifting of 
the tanezumab clinical holds, and an overall risk minimisa-
tion strategy including comprehensive monitoring of joint and 
neurological safety was implemented in subsequent studies. 
The phase III OA programme conducted after the clinical holds 
were removed (post-2015) used only lower doses of tanezumab 
administered subcutaneously in difficult- to- treat patients, incor-
porated extensive risk mitigation and surveillance, excluded 
patients with evidence of or risk factors for RPOA or who were 
unsuitable for joint replacement and restricted chronic concom-
itant use of NSAIDs while in the study.
The current study was designed to assess the efficacy 
(24 weeks) and safety (total 48 weeks, including a 24- week 
post- treatment safety follow- up period) of subcutaneous 
tanezumab (2.5 mg or 5 mg vs placebo, every 8 weeks for a total 
of three doses) in patients with moderate- to- severe OA with an 
inadequate response to, or who could not tolerate, standard- of- 




This was a phase III, randomised, double- blind, placebo- 
controlled, parallel- group, multicentre trial conducted at 104 
hospital, clinical research or general practice sites in Europe 
and Japan from March 2016 to November 2018. Patients were 
recruited directly by investigators, through referrals, and also by 
advertising.
The study comprised a screening period (up to 37 days prior 
to randomisation), a 24- week double- blind treatment period 
and a 24- week safety follow- up period (figure 1). The screening 
period included a washout phase (lasting a minimum of 2 days 
for all prohibited pain medications), if required, and an initial 
pain assessment period (the 7 days prior to randomisation/base-
line) to establish average pain levels in the index joint.
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Patients
Adults (≥18 years of age, male or female) were eligible for 
inclusion if they had a diagnosis of OA of the hip or knee in 
the index joint based on American College of Rheumatology 
criteria12 13 confirmed radiographically (Kellgren- Lawrence14 
grade ≥2) as diagnosed by the Central Readers. They were 
also required to have a documented history of: acetaminophen 
providing insufficient pain relief; and oral NSAIDs providing 
inadequate pain relief or an inability to be taken due to intol-
erance or contraindication; and inadequate pain relief from, or 
intolerance or contraindication to, either tramadol or opioids 
(or unwillingness to take opioids). Other key inclusion criteria 
were Western Ontario and McMaster Universities Osteoarthritis 
Index (WOMAC15) Pain subscale score ≥5 in the index joint 
at screening and baseline, WOMAC Physical Function subscale 
score ≥5 in the index joint at baseline (all as single time points, 
and an increase after washout of analgesics was not required); 
and ‘fair’, ‘poor’ or ‘very poor’ Patient’s Global Assessment of 
OA (PGA- OA) at baseline.
Key exclusion criteria were radiographic evidence of specified 
bone or joint conditions (RPOA, atrophic or hypotrophic OA, 
subchondral insufficiency fracture, spontaneous osteonecrosis of 
the knee, osteonecrosis or pathological fracture) or other condi-
tions (excessive malalignment of the knee, severe chondrocal-
cinosis, other arthropathies [eg, rheumatoid arthritis], systemic 
metabolic bone disease, large cystic lesions, primary or meta-
static tumour lesions, stress or traumatic fracture) identified by a 
group of centralised musculoskeletal radiologist readers.16 Also 
excluded were those with a history of osteonecrosis or osteo-
porotic fracture, significant trauma or surgery to a knee, hip 
or shoulder within the previous year. Patients with a history of 
carpal tunnel syndrome with signs or symptoms in the 1 year 
prior to screening were excluded, as were those with a history or 
presence of clinically significant neurological disease or psychi-
atric disorder. Use of an oral or intramuscular corticosteroid 
within the last 30 days, intra- articular corticosteroid injection 
in the index joint within 12 weeks or in any other joint within 
the last 30 days, intra- articular hyaluronic acid injection in the 
index joint within 30 days or long- acting hyaluronic acid formu-
lation injection in the index joint within 18 weeks also resulted 
in exclusion.
randomisation and blinding
Patients were randomised in a 1:1:1 ratio, stratified by index 
joint (hip or knee) and most severe Kellgren- Lawrence grade 
(2, 3 or 4) in any hip or knee, to one of three parallel groups: 
tanezumab 2.5 mg, tanezumab 5 mg or matching placebo.
A code was created by the computerised randomisation 
schedule, which was generated and held by a person indepen-
dent of the study. All patients, investigators, study coordinators, 
clinical site staff, clinical research associates and the sponsor’s 
staff directly involved in the study were blinded.
Procedures
All study treatments (placebo, tanezumab 2.5 mg and 
tanezumab 5 mg) were provided by Pfizer in matching glass 
prefilled syringes. Treatments were administered subcutane-
ously (1 mL) into the abdomen or anterior thigh by study site 
staff at baseline, week 8 and week 16.
Use of non- study analgesic medication was restricted through 
week 32, as detailed below. After week 32, patients could be 
started on any standard treatment for OA pain.
Except for the 24 hours prior to any study visit for efficacy 
assessments, acetaminophen (rescue therapy, up to 4000 mg/day or 
as permitted by local or national labelling) was allowed during the 
initial pain assessment period and up to 5 days/week up to week 
24, and then as needed until week 32. Limited use of NSAIDs 
(prescription or over- the- counter, ≤10 days per 8- week period, 
total ≤40 days) was permitted on an occasional basis until week 
32 for self- limiting conditions not related to OA, but not within 
48 hours or five half- lives, whichever was greater, of study visits 
for efficacy assessments. All other analgesics were prohibited from 
48 hours prior to the screening initial pain assessment period until 
week 32.
efficacy outcomes
The three co- primary efficacy end points were change from 
baseline to week 24 in WOMAC15 Pain subscale score, WOMAC 
Physical Function subscale score and PGA- OA score. WOMAC 
Pain and Physical Function subscale scores assessed symptoms 
over the previous 48 hours in the index joint on an 11- point 
numeric rating scale (NRS) and PGA- OA was rated on a 5- point 
Likert scale. An electronic device was used during clinic visits 
to complete the study questionnaires, including WOMAC and 
PGA- OA.
Key secondary end points included the proportion of patients 
achieving at least 50% reduction in WOMAC Pain subscale score 
at week 24, change from baseline to week 2 in WOMAC Pain 
subscale score and change from baseline to week 1 in the average 
pain score in the index joint. Patients used an electronic diary 
to rate their average pain in the index joint over the previous 
24 hours on an 11- point NRS (from 0=no pain to 10=worst 
possible pain). Other secondary end points included the propor-
tion of patients achieving at least 30%, 70% and 90% reductions 
in WOMAC Pain subscale score at week 24.
safety outcomes
Safety assessments included treatment- emergent adverse events 
(AEs), physical examination, laboratory tests, vital signs and 
orthostatic blood pressure, 12- lead electrocardiograms and anti-
tanezumab antibody assessments. AEs were coded using Medical 
Dictionary for Regulatory Activities V.21.1 and severity and 
causality were assessed by study investigators. AEs were consid-
ered serious based on established definitions (those that were 
fatal or life- threatening, required new or extended hospitalisa-
tion or resulted in significant or persistent disability, or birth 
defects).17
Joint safety monitoring included radiography of bilateral hips, 
knees and shoulders at screening, week 24 and week 48, eval-
uated by a Central Reader. After the baseline visit, the Central 
Reader requested follow- up MRI if there were equivocal radio-
graphic findings that required investigation. Musculoskeletal 
examinations, evaluation of relevant AEs and monitoring of pain 
scores to detect increased, severe, persistent joint pain occurred 
throughout the study. Investigators could request imaging, 
including MRI, to evaluate patients who reported increased, 
severe, persistent pain. Those images were also evaluated by 
the Central Reader. All possible or probable joint safety events 
identified by the Central Reader or the investigator, and all total 
joint replacements (TJRs), for any reason, were reviewed by a 
blinded Adjudication Committee (comprised of external experts 
in orthopaedic surgery, orthopaedic pathology, rheumatology 
and musculoskeletal radiology).
Joint safety was evaluated based on the numbers of patients 
with adjudicated joint safety end points (RPOA type 1 or type 
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2, subchondral insufficiency fracture, primary osteonecrosis or 
pathological fracture) and TJRs. RPOA type 1 was defined as 
a significant loss of joint space width ≥2 mm (predicated on 
optimal joint positioning) within approximately 1 year, without 
gross structural failure; RPOA type 2 was defined as abnormal 
bone loss or destruction, including limited or total collapse of 
at least one subchondral surface, that is not normally present in 
conventional end- stage OA.18
Neurological assessment included the Neuropathy Impair-
ment Score19 and Survey of Autonomic Symptoms.20 Patients 
were evaluated by a consulting neurologist if an AE of periph-
eral neuropathy or abnormal peripheral sensation was reported 
as serious or severe, caused study withdrawal or was unresolved 
at the end of study participation; or if there was a clinically 
significant neurological examination abnormality which met 
one or more of the criteria noted above. Patients with AEs of 
any seriousness or severity that were suggestive of sympathetic 
autonomic neuropathy (ie, bradycardia, orthostatic hypotension, 
syncope, anhidrosis or hypohidrosis) were evaluated by a cardi-
ologist or neurologist, as specified in the protocol.
statistical analysis
From two previous clinical trials ( ClinicalTrials. gov, 
NCT0073390221 and NCT0074447122), treatment differences 
between tanezumab 2.5 mg/tanezumab 5 mg and placebo were 
assumed to be –0.75/–0.77 for WOMAC Pain, –1.01/–1.05 
for WOMAC Physical Function and –0.25/–0.34 for PGA- OA, 
and within- group SD were 2.76, 2.63 and 0.94 for the three 
outcomes, respectively. A sample size of 270 patients per treat-
ment group was estimated to provide ~80% power to achieve 
statistical significance at the 5% two- sided level for the two 
comparisons of tanezumab (2.5 mg and 5 mg) versus placebo 
over all three co- primary end points.
The primary efficacy population comprised all those 
randomised who received ≥1 dose of study treatment. Safety 
was also assessed in this population.
The graphical approach of gatekeeping strategy23 was 
applied for co- primary and key secondary end points to 
control the family- wise type 1 error rate of 5% (two- sided). 
The co- primary efficacy end points were analysed using 
analysis of covariance (ANCOVA), with model terms for 
baseline score of the corresponding end point, baseline diary 
average pain, index joint (knee or hip), highest Kellgren- 
Lawrence grade and treatment group, with study site as a 
random effect. Missing data at week 24 were handled with 
a multiple imputation strategy dependent on the reason for 
discontinuation. Based on the gatekeeping strategy, co- pri-
mary end points of tanezumab 5 mg were first tested versus 
placebo and, if statistically significant (p≤0.05), co- primary 
end points of tanezumab 2.5 mg were then tested versus 
placebo. A tanezumab treatment group was considered supe-
rior to placebo only if all three co- primary end points were 
statistically significant. Gated by the primary analysis (ie, 
conducted if the co- primary end points were statistically 
significant for both treatment groups), the key secondary 
end points were tested using logistic regression (WOMAC 
Pain responders) and ANCOVA (WOMAC Pain at week 2 
and average pain at week 1).
Unblinded safety data were reviewed regularly throughout by 
an independent, external Data Monitoring Committee.
SAS software V.9.4 (SAS Institute, Cary, North Carolina, USA) 
was used for all statistical analyses. The study was registered on 
ClinicalTrials. gov (NCT02709486).
Patient and public involvement
This research was done without patient involvement in the 
design of the study: the research question was derived from 
the tanezumab phase III development programme, as agreed 
with regulatory agencies. The study design was based on earlier 
studies, using outcome measures that had been developed/
validated academically with patient participation. The patients 
were recruited directly by investigators, through referrals and 
also by advertising, and gave their written informed consent 
after explanation of the details of the trial. They were not asked 
to assess the burden of the intervention or time required. The 
research findings will be disseminated via the standard channels, 
including a plain language summary.
resulTs
Of the 2145 patients who were screened, 849 were randomised 
between 29 March 2016 and 21 December 2017 and all of 
them received study medication; 58.2% (1248/2145) of patients 
screened did not meet the study entry criteria, mostly due to 
insufficient pain or not meeting the radiographic criteria 
(figure 2). During the double- blind treatment period, most 
patients received all three planned doses of study medication 
(85.8% for placebo, 93.3% for tanezumab 2.5 mg and 93.0% 
for tanezumab 5 mg). The double- blind 24- week treatment 
period was completed by 750 (88.3%) patients, 696 (82.0%) 
completed both the treatment and safety follow- up periods and 
726 (85.5%) completed the 24- week safety follow- up period. 
All 849 patients contributed to both efficacy and safety datasets 
(figure 2).
Demographics and baseline characteristics were comparable 
across treatment groups (table 1). The age of the population 
ranged from 26 to 89 years and the majority (587/849, 69.1%) 
were female; for 83.0% (705/849) of the patients, their OA 
index joint was a knee.
At week 24, there was a statistically significant improvement 
from baseline in all three co- primary end points for patients 
receiving tanezumab 5 mg compared with placebo: WOMAC 
Pain (least squares (LS) mean difference±SE–0.62±0.18, 
p=0.0006), WOMAC Physical Function (–0.71±0.17, 
p<0.0001) and PGA- OA (–0.19±0.07, p=0.0051) (figure 3). 
Tanezumab 2.5 mg was not statistically significantly better than 
placebo for all three co- primary end points: at week 24 there 
was a statistically significant improvement for WOMAC Pain 
(–0.46±0.18, p=0.0088) and Physical Function (–0.59±0.18, 
p=0.0008), but PGA- OA (–0.11±0.07, p=0.1092) was not 
significantly different from placebo (figure 3).
From the predefined gatekeeping strategy, because the PGA- OA 
end point was not met for the tanezumab 2.5 mg treatment group, 
further hypothesis testing of the three key secondary end points 
for both tanezumab treatment groups could not be performed. 
Without adjustment for multiple comparisons, the three key 
secondary efficacy end points for both the tanezumab 5 mg and 
tanezumab 2.5 mg treatment groups were better than the placebo 
treatment group (all nominal p≤0.05) (table 2). The proportion 
of patients achieving at least a 50% reduction from baseline in 
WOMAC Pain subscale score at week 24 was 33.8% (placebo), 
45.4% (tanezumab 2.5 mg) and 47.9% (tanezumab 5 mg), with a 
similar pattern for the other categories of response (≥30%, ≥70%, 
≥90%) (figure 4).
During the double- blind treatment period, a total of 55.0%, 
53.0% and 57.0% of patients in the placebo, tanezumab 2.5 mg and 
tanezumab 5 mg groups, respectively, experienced AEs (table 3). 
During this period, arthralgia was the most common AE in the 
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Figure 2 Patient disposition. *Patients screened but not randomised for a reason not related to a specific eligibility criterion. †After either 
completing the treatment period or discontinuing the treatment period.
placebo group, and of AEs that occurred in ≥3% of patients 
in any of the groups, back pain and OA were more frequent 
in both tanezumab treatment groups than placebo (table 3). 
Study discontinuations due to AEs were similar across the three 
groups (table 3). Serious AEs occurred in 1.1% (placebo), 2.8% 
(tanezumab 2.5 mg) and 3.2% (tanezumab 5 mg) of patients 
during the double- blind treatment period (table 3), and none 
was considered treatment- related by investigators. There were 
two deaths during the double- blind treatment period in the 
tanezumab 5 mg group, and neither were considered treatment- 
related (table 3).
Of the 79 patients requiring adjudication for joint safety, most 
(58/79, 73.4%) were adjudicated as normal progression of OA 
(table 4). A total of 14 patients had an adjudicated joint safety 
end point, all receiving tanezumab, including 1.4% (4/283) and 
2.8% (8/284) adjudicated as RPOA in the tanezumab 2.5 mg and 
tanezumab 5 mg groups, respectively (table 4).
A total of eight joints in eight patients were adjudicated as RPOA 
type 1, of which three of eight were in the tanezumab 2.5 mg 
group: these included two knees (baseline Kellgren- Lawrence 
grades 0 and 1, both non- index joints) and one index hip (baseline 
Kellgren- Lawrence grade 3). The other five joints with RPOA type 
1 were in the tanezumab 5 mg group: these were all knees of base-
line Kellgren- Lawrence grade 2 (four joints, of which three were 
index joints and one was a non- index joint) or 3 (one non- index 
joint). Two of the eight joints affected by RPOA type 1 underwent 
TJR (both baseline Kellgren- Lawrence grade 3, of which one was 
the index hip in the tanezumab 2.5 mg group and one a non- index 
knee in the tanezumab 5 mg group).
A total of four joints in four patients were adjudicated as 
RPOA type 2, of which one of four was in the tanezumab 2.5 mg 
group, and was an index hip (baseline Kellgren- Lawrence grade 
4) which underwent TJR. The other three joints with RPOA type 
2 were in the tanezumab 5 mg group: all were hips (one index 
and two non- index) of baseline Kellgren- Lawrence grade 3, of 
which one (the index joint) underwent TJR.
One patient in the tanezumab 5 mg group had a joint adju-
dicated as primary osteonecrosis, a non- index hip with base-
line Kellgren- Lawrence grade 0 that did not undergo TJR. One 
patient in the tanezumab 2.5 mg group had a joint adjudicated as 
subchondral insufficiency fracture, a non- index knee with base-
line Kellgren- Lawrence grade 2 that did not undergo TJR.
Overall, there were 63 TJRs in 61 patients, evenly distrib-
uted across the three treatment groups with the majority 
(54/63, 85.7%) being index joints (table 4). In most cases, 
the joint replacement surgery was considered to be elec-
tive (40/63, 63.5%), that is, not associated with an AE or 
an adjudicated joint safety end point. Four patients (4/61, 
6.6%) had a TJR during the treatment period (0, two and 
two patients in the placebo, tanezumab 2.5 mg and tane-
zumab 5 mg treatment groups, respectively), 52 patients 
(52/61, 85.2%) after completing treatment but during, or 
after completing or discontinuing the safety follow- up period 
(15, 19 and 18 patients in the placebo, tanezumab 2.5 mg and 
tanezumab 5 mg treatment groups, respectively) and five 
patients (5/61, 8.2%) after discontinuing treatment and 
continuing or not in the safety follow- up period (four, one and 
0 patients in the placebo, tanezumab 2.5 mg and tanezumab 
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Sex, n (%) Male 86 (30.5%) 85 (30.0%) 91 (32.0%)
Female 196 (69.5%) 198 (70.0%) 193 (68.0%)
Age, years Mean (SD) 64.2 (9.6) 65.2 (8.4) 65.2 (10.2)
Range 26–87 41–88 32–89
Race, n (%) White 247 (87.6%) 245 (86.6%) 248 (87.3%)
Black or African- American 0 0 0
Asian 34 (12.1%) 38 (13.4%) 34 (12.0%)
Other 1 (0.4%) 0 2 (0.7%)
Body mass index, kg/m2 Mean (SD) 30.4 (4.8) 29.9 (4.8) 30.3 (4.6)
Range 20–39 20–39 17–39
Time since index joint OA diagnosis, years Mean 7.4 6.0 6.7
Range 0–37.9 0–30.6 0–37.7
Index joint, n (%) Hip 47 (16.7%) 49 (17.3%) 48 (16.9%)
Knee 235 (83.3%) 234 (82.7%) 236 (83.1%)
Kellgren- Lawrence grade of index joint, n (%)* 0 0 2 (0.7)† 0
1 0 0 0
2 59 (20.9%) 49 (17.3%) 58 (20.4%)
3 123 (43.6%) 131 (46.3%) 121 (42.6%)
4 100 (35.5%) 101 (35.7%) 105 (37.0%)
WOMAC Pain subscale score Mean (SD) 6.59 (0.94) 6.70 (0.94) 6.60 (0.89)
Range 4.4–9.4 2.8–10.0 4.6–9.6
WOMAC Physical Function subscale score Mean (SD) 6.67 (0.87) 6.77 (0.87) 6.76 (0.88)
Range 5.1–9.4 4.9–9.8 4.6–9.4
PGA- OA score, n (%) Very good 0 0 1 (0.4%)
Good 0 0 1 (0.4%)
Fair 145 (51.6%) 132 (46.8%) 136 (47.9%)
Poor 117 (41.6%) 129 (45.7%) 129 (45.4%)
Very poor 19 (6.8%) 21 (7.4%) 17 (6.0%)
*Kellgren- Lawrence grade for classifying OA severity, ranging from 0 (no OA) to 4 (severe OA).
†In the tanezumab 2.5 mg group, two patients with OA grade 0 were included as a result of protocol deviations.
OA, osteoarthritis; PGA- OA, Patient’s Global Assessment of osteoarthritis; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index.
5 mg treatment groups, respectively). Two of the patients, both 
in the placebo group, underwent TJR in a second joint.
During the double- blind treatment period, paraesthesia 
and hypoaesthesia were more frequent with tanezumab 5 mg 
than placebo, and hypoaesthesia was also more frequent with 
tanezumab 2.5 mg than placebo (table 3). No patients had 
severe paraesthesia or hypoaesthesia; one patient with mild 
hypoaesthesia discontinued treatment in the tanezumab 5 mg 
group and had a final diagnosis of carpal tunnel syndrome 
(table 3). During the treatment period, carpal tunnel 
syndrome was observed in three patients, including two in the 
tanezumab 2.5 mg group and one in the tanezumab 5 mg group. 
A total of 22 patients reported an AE which required a neuro-
logical consultation. Following review of the clinical informa-
tion for these patients, a blinded external neurologist reported 
primary diagnoses of radiculopathy (one, five and three 
patients in the placebo, tanezumab 2.5 mg and tanezumab 5 mg 
groups, respectively), mononeuropathy (one, five and three 
patients, respectively) and polyneuropathy (one patient in the 
tanezumab 2.5 mg group), with other patients having no neuro-
pathic symptoms or signs (one patient in the placebo group) or 
neuropathic symptoms but no clinically significant signs (one 
patient each in the placebo and tanezumab 2.5 mg groups).
AEs potentially related to sympathetic nervous system func-
tion occurred with low frequencies in all treatment groups 
during the double- blind treatment period, including bradycardia 
(two, two and four patients in the placebo, tanezumab 2.5 mg 
and tanezumab 5 mg groups, respectively), orthostatic hypoten-
sion (0, 0 and three patients, respectively) and syncope (0, 0 
and one patient, respectively). Based on protocol- specified cardi-
ology or neurology consultations for patients reported to have 
AEs potentially related to sympathetic nervous system function, 
study investigators determined that no patient in any treatment 
group was considered to have a sympathetic neuropathy.
dIsCussIOn
This study showed that in patients who have not responded to or 
could not tolerate standard- of- care analgesics, tanezumab 5 mg, 
administered subcutaneously, statistically significantly improved all 
three co- primary efficacy end points at 24 weeks: WOMAC Pain, 
WOMAC Physical Function and PGA- OA. Tanezumab 2.5 mg 
improved WOMAC Pain and WOMAC Physical Function, but 
was not statistically significant on the PGA- OA end point at week 
24. The proportion of patients achieving at least a 50% reduc-
tion from baseline in WOMAC Pain at week 24 was 33.8% for 
placebo, compared with 45.4% for tanezumab 2.5 mg and 47.9% 
for tanezumab 5 mg (figure 4) and rates of discontinuation due 
to insufficient clinical response were low (figure 2). Tanezumab 
was generally well tolerated through the 24- week treatment and 
24- week safety follow- up periods, with similarly low rates of 
discontinuations due to AEs observed among patients receiving 
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Figure 3 Change from baseline to week 24 in the co- primary end points: WOMAC Pain subscale score, WOMAC Physical Function subscale score 
and PGA- OA score. *p≤0.05; **p≤0.01; ***p≤0.001 vs placebo. WOMAC Pain assessed pain over the previous 48 hours in the index joint, and was 
the mean of five questions each scored on an 11- point numerical rating scale (NRS), from 0 to 10 with higher score indicating more pain. WOMAC 
Physical Function assessed ability to move around and perform activities of daily living over the previous 48 hours in the index joint, and was the 
mean of 17 questions each scored on an 11- point NRS, from 0 to 10 with higher score indicating worse function. PGA- OA was rated on a 5- point 
Likert scale from 1=‘very good’ (asymptomatic and no limitation of normal activities) to 5=‘very poor’ (very severe symptoms which are intolerable 
and inability to carry out all normal activities) in answer to the question “Considering all the ways your osteoarthritis in your hip/knee affects you, 
how are you doing today?” Reproduced from Berenbaum F, Blanco F, Guermazi A, Vignon E, Miki K, Yamabe T, Viktrup L, Junor R, Carey W, Brown M, 
Verburg K, West C. Ann Rheum Dis. 2019;78(suppl 2):262–263, with permission from BMJ Publishing Group Ltd. LS, least squares; PGA- OA, Patient’s 
Global Assessment of osteoarthritis; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index.







Treatment response: ≥50% reduction from 
baseline in WOMAC Pain at week 24*
Number of patients with treatment response 95 (33.8%) 128 (45.4%) 136 (47.9%)
Odds ratio vs placebo 1.72 1.87
P value† 0.0022 0.0004
WOMAC Pain: change from baseline to week 
2‡
LS mean (SE) –1.35 (0.14) –2.02 (0.14) –1.69 (0.14)
LS mean difference vs placebo (SE) –0.67 (0.14) –0.34 (0.14)
P value† <0.0001 0.0149
Average pain score: change from baseline to 
week 1‡
LS mean (SE) –0.57 (0.11) –1.06 (0.11) –0.93 (0.11)
LS mean difference vs placebo (SE) –0.49 (0.11) –0.36 (0.11)
P value† <0.0001 0.0009
*Mixed baseline/last observation carried forward.
†Nominal, unadjusted p value. In line with the predefined gatekeeping strategy, hypothesis testing of the three key secondary end points could not be performed: no key 
secondary end points can be declared as statistically significantly better than placebo treatment.
‡Multiple imputation.
LS, least squares; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index.
tanezumab and placebo. TJRs were similarly distributed across 
all three treatment groups. Adjudicated joint safety end points 
occurred only in tanezumab- treated patients, and more frequently 
with tanezumab 5 mg than tanezumab 2.5 mg.
The efficacy observed in the current study is supported by two 
previous placebo- controlled studies in patients with knee21 or 
hip22 OA that administered tanezumab 2.5 mg and 5 mg intrave-
nously, with both doses resulting in improvement across most of 
the end points at week 24 (online supplementary tables 1 and 2: 
some of the 24- week data are previously unpublished). As with 
the current study, significant improvements in WOMAC Pain 
and Physical Function were seen with tanezumab 2.5 mg at week 
24 in both those intravenous studies. The tanezumab 5 mg dose 
did not reach significance on WOMAC Pain or the PGA- OA at 
week 24 in the intravenous knee study (online supplementary 
table 1). The placebo response for PGA- OA at week 24 was 
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Figure 4 Proportion of patients achieving at least 30%, 50%, 70% and 90% reductions in WOMAC Pain subscale score at week 24. *P≤0.05; 
**p≤0.01; ***p≤0.001 vs placebo. Mixed baseline/last observation carried forward. Nominal, unadjusted p value. In line with the predefined 
gatekeeping strategy, hypothesis testing of the three key secondary end points could not be performed: no key secondary end points can be declared 
as statistically significantly better than placebo treatment. WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index.
larger in the current study (–0.72, figure 3) than that observed in 
these earlier intravenous studies (–0.33 to –0.52, online supple-
mentary tables 1 and 2).
The large placebo response on the PGA- OA end point in the 
current study may potentially have contributed to the failure 
of the tanezumab 2.5 mg dose to reach statistical significance 
on this end point. Contextual factors can contribute consid-
erably to the treatment effect in OA,24 with multiple factors 
influencing the size of the placebo response,25 and it is possible 
that treatment expectations were high in the current difficult- 
to- treat population receiving subcutaneous injection of a medi-
cation previously shown to be effective. A reduced treatment 
response to tanezumab or an administration route effect cannot 
be excluded, but there were also differences in patient popu-
lations. It should also be noted that some pre- hold OA studies 
(conducted before 2015) had a flare design. The current study 
was conducted in Europe and Japan in patients with moderate- 
to- severe OA for whom standard- of- care treatment was inad-
equate or unsuitable. Baseline WOMAC Pain scores were less 
severe in the current population compared with the previous 
intravenous tanezumab knee21 and hip22 OA studies, although 
baseline joint radiographic findings were more severe, with 36% 
of patients with Kellgren- Lawrence grade 4 in the current study 
compared with <21% in the previous studies.21 22 The associa-
tion between pain and radiographic findings has not always been 
consistent,26 but a relationship has been reported for knee OA.27 
Overall, the proportion of patients with a moderate (≥30%) 
or substantial (≥50%) clinically important improvement in 
WOMAC Pain28 with tanezumab compared with placebo at 24 
weeks was statistically significant in the current study, although 
smaller than observed in the intravenous tanezumab knee21 and 
hip22 studies (online supplementary tables 1 and 2). Notwith-
standing the limitation in dichotomising continuous data,29–32 an 
effect size (placebo- adjusted LS mean change divided by model- 
based SD) of 0.20 has been proposed as the lower bound for 
a small meaningful effect (or change in pain).33 In our study, 
the effect size (placebo- adjusted) for tanezumab 2.5 mg and 5 mg 
dose regimens at week 24 was modest at 0.24 (0.46/1.93=0.24) 
and 0.32 (0.62/1.93=0.32), respectively, although both above 
the suggested lower threshold for meaningfulness.
In the current study, tanezumab was generally well toler-
ated during the 24- week treatment period, with similarly 
low rates of discontinuation due to AEs observed among 
patients taking tanezumab and placebo. The observed AEs 
were consistent with previous studies,9 21 22 34 35 with no new 
safety signals identified. Paraesthesia was more frequent with 
tanezumab 5 mg than placebo, and hypoaesthesia was more 
frequent with both tanezumab doses than placebo. TJRs were 
similarly distributed across all three treatment groups, mostly in 
joints with a baseline Kellgren- Lawrence grade of 3 or 4. Non- 
elective joint replacements were more frequent in the tane-
zumab 5 mg treatment group (11/20 joints, 55.0%) compared 
with tanezumab 2.5 mg (6/22 joints, 27.3%) or placebo (6/21 
joints, 28.6%). Adjudicated joint safety end points were only 
reported in tanezumab- treated patients, and there were twice 
as many cases of RPOA type 1 (n=8) than RPOA type 2 
(n=4) (table 4). The tanezumab 5 mg treatment group had the 
highest incidence of RPOA type 1, RPOA type 2 and primary 
osteonecrosis (one case), whereas the only subchondral insuf-
ficiency fracture was observed in the tanezumab 2.5 mg group. 
OA is frequently a multijoint disease, and the joints adjudi-
cated as RPOA included both index and non- index joints. All 
four joints adjudicated as RPOA type 2 in the tanezumab treat-
ment groups had a baseline Kellgren- Lawrence grade of 3 or 4. 
There were three joints with baseline Kellgren- Lawrence grade 
0 or 1, which were adjudicated as RPOA type 1 (two joints in 
the tanezumab 2.5 mg treatment group) or osteonecrosis (one 
joint in the tanezumab 5 mg treatment group).
The frequency of RPOA in the current study (12/567, 2.1% 
of tanezumab- treated patients) is higher than that seen in a 
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Table 3 Summary of treatment- emergent adverse events (AEs) reported by the investigator
Patients, n (%)
Treatment period
(first dose to week 24)
up to end of study













Any AE 155 (55.0%) 150 (53.0%) 162 (57.0%) 178 (63.1%) 184 (65.0%) 198 (69.7%)
Serious AE*† 3 (1.1%) 8 (2.8%) 9 (3.2%) 11 (3.9%) 24 (8.5%) 27 (9.5%)
Treatment- related AE 40 (14.2%) 42 (14.8%) 48 (16.9%) 46 (16.3%) 52 (18.4%) 59 (20.8)
Discontinued study medication due to AE (and 
continued study)
7 (2.5%) 3 (1.1%) 4 (1.4%) 7 (2.5%) 3 (1.1%) 4 (1.4%)
Discontinued study due to AE 2 (0.7%) 5 (1.8%) 1 (0.4%) 2 (0.7%) 6 (2.1%) 4 (1.4%)
Most common AEs‡             
  Arthralgia 34 (12.1%) 27 (9.5%) 23 (8.1%) 54 (19.1%) 53 (18.7%) 47 (16.5%)
  Nasopharyngitis 25 (8.9%) 31 (11.0%) 22 (7.7%) 33 (11.7%) 39 (13.8%) 30 (10.6%)
  Back pain 15 (5.3%) 16 (5.7%) 17 (6.0%) 23 (8.2%) 27 (9.5%) 25 (8.8%)
  Headache 18 (6.4%) 15 (5.3%) 14 (4.9%) 21 (7.4%) 20 (7.1%) 16 (5.6%)
  Osteoarthritis 5 (1.8%) 9 (3.2%) 13 (4.6%) 9 (3.2%) 17 (6.0%) 26 (9.2%)
  Paraesthesia 5 (1.8%) 5 (1.8%) 12 (4.2%) 6 (2.1%) 6 (2.1%) 12 (4.2%)
  Influenza 5 (1.8%) 5 (1.8%) 9 (3.2%) 5 (1.8%) 9 (3.2%) 11 (3.9%)
  Fall 8 (2.8%) 12 (4.2%) 7 (2.5%) 13 (4.6%) 19 (6.7%) 9 (3.2%)
  Pain in extremity 7 (2.5%) 9 (3.2%) 5 (1.8%) 11 (3.9%) 16 (5.7%) 9 (3.2%)
  Musculoskeletal pain 7 (2.5%) 6 (2.1%) 7 (2.5%) 14 (5.0%) 13 (4.6%) 11 (3.9%)
  Joint swelling 3 (1.1%) 6 (2.1%) 8 (2.8%) 4 (1.4%) 7 (2.5%) 10 (3.5%)
  Neck pain 4 (1.4%) 3 (1.1%) 2 (0.7%) 10 (3.5%) 5 (1.8%) 4 (1.4%)
  Urinary tract infection 4 (1.4%) 6 (2.1%) 2 (0.7%) 6 (2.1%) 9 (3.2%) 4 (1.4%)
  Rapidly progressive osteoarthritis 0 1 (0.4%) 2 (0.7%) 0 4 (1.4%) 11 (3.9%)
AE of abnormal peripheral sensation§             
  Paraesthesia 5 (1.8%) 5 (1.8%) 12 (4.2%) 6 (2.1%) 6 (2.1%) 12 (4.2%)
  Hypoaesthesia¶ 2 (0.7%) 4 (1.4%) 6 (2.1%) 2 (0.7%) 7 (2.5%) 7 (2.5%)
  Decreased vibratory sense 3 (1.1%) 0 1 (0.4%) 3 (1.1%) 1 (0.4%) 2 (0.7%)
AEs based on the usual definition for clinical trials. A blinded adjudication committee reviewed all possible or probable joint safety events resulting in differences in reported 
joint AEs (table 3) and adjudicated joint events (table 4).
*AEs were considered serious based on established definition.17 During the double- blind treatment period, three patients in the placebo group had serious AEs, including one 
with cataract, one with osteoarthritis and one with lymphatic fistula. Eight patients in the tanezumab 2.5 mg group had serious AEs, including three with four nerve injuries 
or bone fractures, one with acute myocardial infarction and coronary artery stenosis and one each with ocular vascular disorder, cerebrovascular accident, osteoarthritis and 
rotator cuff syndrome. Nine patients in the tanezumab 5 mg group had serious AEs, including two with three hepatobiliary disorders, two with osteoarthritis and one each with 
arrhythmia, cardiorespiratory arrest, pancreatitis, nasopharyngitis, pneumonia and arthralgia.
†There were three deaths during the study. Two deaths occurred during the double- blind treatment period in patients in the tanezumab 5 mg treatment group: neither were 
considered by the investigator to be related to study medication (one patient, aged 81 years, died on study day 90, with the cause of death reported as severe cold with probable 
influenza virus infection. The other patient, aged 77 years, was found dead at home on study day 114; the event was reported as cardiorespiratory arrest). The third patient aged 
60 years, in the tanezumab 2.5 mg treatment group, died of cerebrovascular accident. This patient was lost to follow- up and the death was not confirmed by the family or the 
doctor (it was stated on a returned letter that had been sent to the patient by the study site as part of attempts by the investigator to make contact with the patient).
‡Reported in ≥3% of patients in any treatment group up to end of study.
§Reported in ≥1% of patients in any treatment group during the treatment period.
¶One patient with mild hypoaesthesia of the left index finger discontinued treatment in the tanezumab 5 mg group after two doses of study drug, completed the safety follow- 
up period and the adverse event was ongoing at study end. The patient was evaluated by a local neurologist and cervical spine MRI showed disc protrusion at C5- C6 and C6- C7 
and a nerve conduction study showed a mild left- sided carpal tunnel syndrome. The external expert neurologist considered the patient to have had carpal tunnel syndrome.
similarly designed but shorter 16- week North American study 
with less exposure to the 5 mg dose (6/464, 1.3%) and fewer 
patients with Kellgren- Lawrence grade 4 OA.34 Comparison of 
data from the current study with data from previous tanezumab 
studies (conducted before 2015) that did not include risk mitiga-
tion measures and enhanced surveillance for joint safety events is 
difficult.
The comprehensive joint safety assessment used in the current 
tanezumab development programme was strengthened after the 
clinical holds were removed and provides radiographic and symp-
tomatic details on the natural progression of OA in patients with or 
without treatment. The sequential radiography allows for identifi-
cation of RPOA type 1 that was not done before, and the Central 
Reader and Adjudication Committee evaluation of imaging allow 
for a more precise identification of RPOA type 2 cases. These 
features may help to identify a potential correlation between 
RPOA type 1 and type 2 and better characterise the risk- benefit 
of tanezumab in patients with OA. As the pathophysiology of 
RPOA is poorly understood,10 the tanezumab clinical programme 
represents the largest dataset available to evaluate RPOA.
The strengths of this study compared with the pre- hold 
programme (studies conducted before 2015) include the recruit-
ment of difficult- to- treat patients and comprehensive joint 
safety and sympathetic neurological surveillance, and 24- week 
safety follow- up. The limitations include a relatively high rate 
of screening failures. Understanding of the pathogenesis of joint 
safety events seen with tanezumab, and how this is similar to 
or different from the rapid joint space narrowing or rapidly 
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Patients adjudicated for joint safety, n (%) 19 (6.7%) 27 (9.5%) 33 (11.6%)
  Patients with adjudicated joint safety end point 0 5 (1.8%) 9 (3.2%)
   RPOA 0 4 (1.4%) 8 (2.8%)
    Type 1 0 3 (1.1%) 5 (1.8%)
    Type 2 0 1 (0.4%) 3 (1.1%)
   Primary osteonecrosis 0 0 1 (0.4%)
   Pathological fracture 0 0 0
   Subchondral insufficiency fracture 0 1 (0.4%) 0
Patients with normal OA progression* 17 (6.0%) 22 (7.8%) 19 (6.7%)
Patients with other joint outcome* 2 (0.7%) 0 5 (1.8%)
Total joint replacement
  Patients with ≥1 total joint replacement, n (%) 19 (6.7%)† 22 (7.8%) 20 (7.0%)
  Number of joints 21 22 20
   Index/non- index 16/5 21/1 17/3
   Elective/non- elective‡ 15/6 16/6 9/11
   Knee/hip/shoulder/other 8/13/0/0 13/9/0/0 10/9/1/0
   Baseline Kellgren- Lawrence grade 0/1/2/3/4 0/1/1/13/6 0/0/1/5/16 0/0/1/8/9
RPOA type 1 was defined as a significant loss of joint space width ≥2 mm (predicated on optimal joint positioning) within approximately 1 year, without gross structural failure; RPOA type 2 was 
defined as abnormal bone loss or destruction, including limited or total collapse of at least one subchondral surface, that is not normally present in conventional end- stage osteoarthritis.18
*Excludes any patient who had one or more of the outcomes included in the adjudicated joint safety end point.
†In the placebo group, two patients had two joint replacements.
‡Elective when not associated with an AE or an adjudicated joint safety end point.
AE, adverse event; OA, osteoarthritis; RPOA, rapidly progressive osteoarthritis.
destructive arthropathies seen elsewhere, is currently limited. 
A longer- term active- controlled study (NCT02528188) will 
provide more data to further characterise the risk- benefit of 
tanezumab in patients with OA.
COnClusIOn
This study demonstrates subcutaneous tanezumab at a dose of 
5 mg every 8 weeks statistically significantly improves pain, phys-
ical function and PGA- OA at 24 weeks in patients with moderate- 
to- severe OA who have not responded to or could not tolerate 
standard- of- care analgesics. Tanezumab 2.5 mg improved pain 
and function in patients with moderate- to- severe OA, but did not 
reach statistical significance on the other co- primary end point, 
PGA- OA. Adjudicated joint safety end points occurred only in 
tanezumab- treated patients, with RPOA in 1.4% and 2.8% of 
patients in the tanezumab 2.5 mg and tanezumab 5 mg groups, 
respectively, and in none receiving placebo. The frequency of 
TJR was similar across all three treatment groups.
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